Sorry, you need to enable JavaScript to visit this website.

Competitive Grants Program

Pfizer supports the global healthcare community’s independent initiatives (e.g., research, quality improvement or education) to improve patient outcomes in areas of unmet medical need that are aligned with Pfizer’s medical and/or scientific strategies.

Pfizer’s competitive grant program involves a publicly posted Request for Proposal (RFP) that provides detail regarding a specific area of interest and sets timelines for review and approval. Organizations are invited to submit an application addressing the specific gaps in research, practice or care as outlined in the specific RFP. The grant requester (and ultimately the grantee) is responsible for the design, implementation, sponsorship, and conduct of the independent initiative supported by the grant, including compliance with any regulatory requirements.

Sign up to receive all grant announcements, including Request for Proposal (RFP) postings.

Sign Up for Alerts Details
  • Title
    Grant Type
    Focus Area
    Country
    Application Due Date
    Optimizing Antimicrobial Stewardship (AMS) Interventions and Outcomes in Clinical Outcomes, Optimal Use and Resource Utilizatio
    Release Date:
    Review Process: Pfizer Internal
    Research Inflammation & Immunology China
    Optimizing Disease Management to Improve Alopecia Areata Quality of Care
    Release Date:
    Review Process: Pfizer Internal
    Quality Improvement Inflammation & Immunology China
    Research on Exploring Disease Assessment and Prioritizing Systematic Treatment for Vitiligo
    Release Date:
    Review Process: Pfizer Internal
    Research Inflammation & Immunology China
    Quality Improvement in Molecular Testing Pathways for Metastatic Colorectal Cancer (mCRC)
    Release Date:
    Partner: American Society for Clinical Pathology (ASCP)
    Review Process: Expert Review Panel
    Quality Improvement Oncology USA
    Personalized monitoring&treatment for HR+, HER2- mBC patients treated w CDK4/6i: incorporating Patient complexity risk factors
    Release Date:
    Review Process: Expert Review Panel
    Quality Improvement, Research Oncology Italy
    Providing Appropriate Medical Care for IBD Patients
    Release Date:
    Partner: Japanese Society for Inflammatory Bowel Disease (JSIBD)
    Review Process: Expert Review Panel
    Translation: Japanese (link)
    Quality Improvement Inflammation & Immunology Japan
    Administration of brentuximab vedotin alone or in combination with other approved agents in pre and/or peri CAR-T
    Release Date:
    Review Process: Pfizer Internal
    Research Oncology USA
    Fostering Educational Initiatives for ALK+ Metastatic Non-Small Cell Lung Cancer(mNSCLC) Tyrosine Kinase Inhibitors(TKI) Therapy
    Release Date:
    Review Process: Pfizer Internal
    Translation: French (link)
    Education Oncology Canada
  • Title
    Grant Type
    Focus Area
    Country
    Application Due Date
    Acute Lymphoblastic Leukemia Peer-to-Peer Education & Support
    Release Date:
    Review Process: Pfizer Internal
    Education Oncology USA
    PARP-inhibitor Combination Treatments in Prostate Cancer
    Release Date:
    Review Process: Pfizer Internal
    Education Oncology USA
    Optimizing Patient Access to CDK 4/6 Inhibitors in the Armamentarium Against Metastatic Breast Cancer
    Release Date:
    Review Process: Pfizer Internal
    Education Oncology USA
    Understanding healthcare disparities in Atopic Dermatitis and Alopecia Areata patients
    Release Date:
    Review Process: Pfizer Internal
    Quality Improvement Inflammation & Immunology All
    ADVANCE: Global Awards for Advancing Chronic Pain Research
    Release Date:
    Review Process: Expert Review Panel
    Research Internal Medicine All
    Enhancing the Understanding of Health Maintenance in the Management of IBD
    Release Date:
    Review Process: Pfizer Internal
    Education Inflammation & Immunology USA
    Outpatient Management of COVID-19
    Release Date:
    Review Process: Pfizer Internal
    Education Hospital Albania, Andorra, Armenia, Austria, Azerbaijan, Belarus, Belgium, Bosnia and Herzegovina, Bulgaria, Croatia, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Georgia, Germany, Greece, Hungary, Iceland, Ireland, Israel, Italy, Kazakhstan, Kyrgyzstan, Latvia, Lithuania, Luxembourg, Macedonia, The Former Yugoslav, Malta, Moldova, Republic of, Monaco, Netherlands, Norway, Poland, Portugal, Romania, Russian Federation, Slovakia (Slovak Republic), Slovenia, Spain, Sweden, Switzerland, Tajikistan, Turkey, Turkmenistan, Ukraine, United Kingdom, Uzbekistan
    Emerging Therapies in Alopecia Areata for Dermatologists - United States
    Release Date:
    Review Process: Pfizer Internal
    Education Inflammation & Immunology USA
    Virtual Programs for Rheumatology Education
    Release Date:
    Review Process: Pfizer Internal
    Education Inflammation & Immunology USA
    2021/2022 Global NASH ASPIRE
    Release Date:
    Review Process: Expert Review Panel
    Research Internal Medicine All
    Addressing Knowledge Gaps in Alopecia Areata and Atopic Dermatitis (Global (excluding the US)
    Release Date:
    Review Process: Pfizer Internal
    Education Inflammation & Immunology All
    2021/2022 Global Obesity ASPIRE
    Release Date:
    Review Process: Expert Review Panel
    Research Internal Medicine All